ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT • US04546C3043

12.04 USD
+0.2 (+1.69%)
At close: Feb 23, 2026
11.96 USD
-0.08 (-0.66%)
After Hours: 2/23/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ASRT scores 3 out of 10 in our fundamental rating. ASRT was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of ASRT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ASRT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ASRT had negative earnings in the past year.
  • In the past year ASRT had a positive cash flow from operations.
  • ASRT had negative earnings in 4 of the past 5 years.
  • ASRT had a positive operating cash flow in 4 of the past 5 years.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

  • ASRT has a better Return On Assets (-8.90%) than 68.75% of its industry peers.
  • With a decent Return On Equity value of -26.89%, ASRT is doing good in the industry, outperforming 65.63% of the companies in the same industry.
Industry RankSector Rank
ROA -8.9%
ROE -26.89%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • ASRT's Gross Margin of 68.16% is fine compared to the rest of the industry. ASRT outperforms 78.13% of its industry peers.
  • ASRT's Gross Margin has declined in the last couple of years.
  • ASRT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ASRT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ASRT has been increased compared to 5 years ago.
  • The debt/assets ratio for ASRT is higher compared to a year ago.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ASRT has an Altman-Z score of -2.19. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
  • ASRT has a Altman-Z score of -2.19. This is comparable to the rest of the industry: ASRT outperforms 44.79% of its industry peers.
  • ASRT has a debt to FCF ratio of 3.06. This is a good value and a sign of high solvency as ASRT would need 3.06 years to pay back of all of its debts.
  • The Debt to FCF ratio of ASRT (3.06) is better than 91.15% of its industry peers.
  • ASRT has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.37, ASRT is in line with its industry, outperforming 40.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 3.06
Altman-Z -2.19
ROIC/WACCN/A
WACC9.32%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • ASRT has a Current Ratio of 1.58. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
  • ASRT has a worse Current ratio (1.58) than 69.27% of its industry peers.
  • A Quick Ratio of 1.43 indicates that ASRT should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.43, ASRT is doing worse than 64.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.43
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ASRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.60%, which is quite impressive.
  • Looking at the last year, ASRT shows a quite strong growth in Revenue. The Revenue has grown by 9.21% in the last year.
  • The Revenue for ASRT have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
Revenue 1Y (TTM)9.21%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 33.07% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 3.55% on average per year.
EPS Next Y-90.1%
EPS Next 2Y7.27%
EPS Next 3Y30.49%
EPS Next 5Y33.07%
Revenue Next Year-9.11%
Revenue Next 2Y-3.99%
Revenue Next 3Y0.93%
Revenue Next 5Y3.55%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 -40 60

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • ASRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ASRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ASRT is valued cheaper than 95.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.05
EV/EBITDA -2.25
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • ASRT's earnings are expected to grow with 30.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.27%
EPS Next 3Y30.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ASRT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (2/23/2026, 8:00:01 PM)

After market: 11.96 -0.08 (-0.66%)

12.04

+0.2 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-10
Inst Owners27.28%
Inst Owner Change-86.72%
Ins Owners1.12%
Ins Owner Change-0.04%
Market Cap77.30M
Revenue(TTM)137.35M
Net Income(TTM)-28.45M
Analysts82
Price Target38.19 (217.19%)
Short Float %4.29%
Short Ratio1.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.56%
Min EPS beat(2)-119.3%
Max EPS beat(2)238.41%
EPS beat(4)2
Avg EPS beat(4)2.16%
Min EPS beat(4)-145.1%
Max EPS beat(4)238.41%
EPS beat(8)3
Avg EPS beat(8)-366.43%
EPS beat(12)4
Avg EPS beat(12)-302.51%
EPS beat(16)7
Avg EPS beat(16)-212.97%
Revenue beat(2)2
Avg Revenue beat(2)41.15%
Min Revenue beat(2)2.84%
Max Revenue beat(2)79.46%
Revenue beat(4)3
Avg Revenue beat(4)21.67%
Min Revenue beat(4)-5.64%
Max Revenue beat(4)79.46%
Revenue beat(8)5
Avg Revenue beat(8)11.34%
Revenue beat(12)8
Avg Revenue beat(12)6.31%
Revenue beat(16)12
Avg Revenue beat(16)6.58%
PT rev (1m)0%
PT rev (3m)1306.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2679.49%
EPS NY rev (1m)0%
EPS NY rev (3m)-1290.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-41.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF 6.05
P/OCF 6.05
P/B 0.73
P/tB 1.51
EV/EBITDA -2.25
EPS(TTM)-3
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)1.99
FCFY16.54%
OCF(TTM)1.99
OCFY16.54%
SpS21.39
BVpS16.48
TBVpS7.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.9%
ROE -26.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.16%
FCFM 9.31%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 3.06
Debt/EBITDA 2.65
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 86.6%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.43
Altman-Z -2.19
F-Score4
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
EPS Next Y-90.1%
EPS Next 2Y7.27%
EPS Next 3Y30.49%
EPS Next 5Y33.07%
Revenue 1Y (TTM)9.21%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%69.36%
Revenue Next Year-9.11%
Revenue Next 2Y-3.99%
Revenue Next 3Y0.93%
Revenue Next 5Y3.55%
EBIT growth 1Y0.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.8%
EBIT Next 3Y60.57%
EBIT Next 5Y42.08%
FCF growth 1Y-76.41%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-81.89%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%

ASSERTIO HOLDINGS INC / ASRT FAQ

Can you provide the ChartMill fundamental rating for ASSERTIO HOLDINGS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASRT.


What is the valuation status of ASSERTIO HOLDINGS INC (ASRT) stock?

ChartMill assigns a valuation rating of 2 / 10 to ASSERTIO HOLDINGS INC (ASRT). This can be considered as Overvalued.


What is the profitability of ASRT stock?

ASSERTIO HOLDINGS INC (ASRT) has a profitability rating of 2 / 10.


What is the earnings growth outlook for ASSERTIO HOLDINGS INC?

The Earnings per Share (EPS) of ASSERTIO HOLDINGS INC (ASRT) is expected to decline by -90.1% in the next year.